ArticleJournal of nanobiotechnology2017
Biocompatible coated magnetosome minerals with various organization and cellular interaction properties induce cytotoxicity towards RG-2 and GL-261 glioma cells in the presence of an alternating magnetic field.
Article in Journal of nanobiotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 55 citations in OpenAlex.
- Peptide-Based Nanocomplexes Enable Transferrin-Mediated Uptake and p53-Driven Antitumor Activity in 2D and 3D Glioblastoma Models.International journal of molecular sciences · 2026Article
- Cationic Surface Modification Combined with Collagen Enhances the Stability and Delivery of Magnetosomes for Tumor Hyperthermia.Journal of functional biomaterials · 2025Article
- Neurobiological effects and mechanisms of magnetic fields: a review from 2000 to 2023.BMC public health · 2024Review
- Magnetic Hyperthermia in Glioblastoma Multiforme Treatment.International journal of molecular sciences · 2024Review
- Evidence That a Peptide-Drug/p53 Gene Complex Promotes Cognate Gene Expression and Inhibits the Viability of Glioblastoma Cells.Pharmaceutics · 2024Article
- Neurosurgical Applications of Magnetic Hyperthermia Therapy.Neurosurgery clinics of North America · 2023Review
- Evaluation of cell disruption technologies on magnetosome chain length and aggregation behaviour fromFrontiers in bioengineering and biotechnology · 2023Article
- Progress in affinity ligand-functionalized bacterial magnetosome nanoparticles for bio-immunomagnetic separation of HBsAg protein.PloS one · 2022Article
- Strategy for Avoiding Protein Corona Inhibition of Targeted Drug Delivery by Linking Recombinant Affibody Scaffold to Magnetosomes.International journal of nanomedicine · 2022Article
- Pharmacological strategies for improving the prognosis of glioblastoma.Expert opinion on pharmacotherapy · 2021Article
- Advances in Magnetic Nanoparticles Engineering for Biomedical Applications-A Review.Bioengineering (Basel, Switzerland) · 2021Review
- Biocompatibility of Bacterial Magnetosomes as MRI Contrast Agent: A Long-Term In Vivo Follow-Up Study.Nanomaterials (Basel, Switzerland) · 2021Article
- Immunogenic Cell Death Induced by Chemoradiotherapy of Novel pH-Sensitive Cargo-Loaded Polymersomes in Glioblastoma.International journal of nanomedicine · 2021Article
- Enhancement of T2* Weighted MRI Imaging Sensitivity of U87MG Glioblastoma Cells Using γ-Ray Irradiated Low Molecular Weight Hyaluronic Acid-Conjugated Iron Nanoparticles.International journal of nanomedicine · 2021Article
- Improved methods for mass production of magnetosomes and applications: a review.Microbial cell factories · 2020Review
- Hyperthermia treatment advances for brain tumors.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2020Review
- Natural Metallic Nanoparticles for Application in Nano-Oncology.International journal of molecular sciences · 2020Review
- Review
- Nano-Therapies for Glioblastoma Treatment.Cancers · 2020Review
- A Method for Producing Highly Pure Magnetosomes in Large Quantity for Medical Applications UsingFrontiers in bioengineering and biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiologics magnetics nanoparticles, magnetosomes, attract attention because of their magnetic characteristics and potential applications. The aim of the present study was to develop and characterize novel magnetosomes, which were extracted from magnetotactic bacteria, purified to produce apyrogen magnetosome minerals, and then coated with Chitosan, Neridronate, or Polyethyleneimine. It yielded stable magnetosomes designated as M-Chi, M-Neri, and M-PEI, respectively. Nanoparticle biocompatibility was evaluated on mouse fibroblast cells (3T3), mouse glioblastoma cells (GL-261) and rat glioblastoma cells (RG-2). We also tested these nanoparticles for magnetic hyperthermia treatment of tumor in vitro on two tumor cell lines GL-261 and RG-2 under the application of an alternating magnetic field. Heating, efficacy and internalization properties were then evaluated.
resultsNanoparticles coated with chitosan, polyethyleneimine and neridronate are apyrogen, biocompatible and stable in aqueous suspension. The presence of a thin coating in M-Chi and M-PEI favors an arrangement in chains of the magnetosomes, similar to that observed in magnetosomes directly extracted from magnetotactic bacteria, while the thick matrix embedding M-Neri leads to structures with an average thickness of 3.5 µm
conclusionsCoating of purified magnetosome minerals can therefore be chosen to control the interactions of nanoparticles with cells, organization of the minerals, as well as heating and cytotoxicity properties, which are important parameters to be considered in the design of a magnetic hyperthermia treatment of tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.